NanoViricides Inc
$ 0.97
-7.62%
02 Mar - close price
- Market Cap 22,646,800 USD
- Current Price $ 0.97
- High / Low $ 1.00 / 0.93
- Stock P/E N/A
- Book Value 0.51
- EPS -0.50
- Next Earning Report 2026-05-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.44 %
- ROE -0.78 %
- 52 Week High 2.23
- 52 Week Low 0.85
About
NanoViricides, Inc., a nanobiopharmaceutical company, discovers, develops and markets drugs for the treatment of viral infections. The company is headquartered in Shelton, Connecticut.
Analyst Target Price
$6.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-12-03 | 2025-09-03 | 2025-05-12 | 2025-02-12 | 2024-11-12 | 2024-08-28 | 2024-05-15 | 2024-02-14 | 2023-10-13 | 2023-08-30 | 2023-05-15 |
| Reported EPS | -0.11 | -0.135 | -0.12 | -0.1383 | -0.1391 | -0.228 | -0.19 | -0.16 | -0.18 | -0.15 | -0.3052 | -0.1463 |
| Estimated EPS | -0.14 | -0.18 | -0.2 | -0.19 | -0.18 | -0.17 | -0.31 | -0.19 | -0.19 | -0.17 | -0.17 | -0.17 |
| Surprise | 0.03 | 0.045 | 0.08 | 0.0517 | 0.0409 | -0.058 | 0.12 | 0.03 | 0.01 | 0.02 | -0.1352 | 0.0237 |
| Surprise Percentage | 21.4286% | 25% | 40% | 27.2105% | 22.7222% | -34.1176% | 38.7097% | 15.7895% | 5.2632% | 11.7647% | -79.5294% | 13.9412% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-19 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NNVC
2026-02-21 11:00:00
NanoViricides CEO Dr. Anil Diwan discussed the progress of their broad-spectrum antiviral candidate NV-387, including the completion of the clinical trial application for a Phase 2 Mpox study in the Democratic Republic of Congo, which is fully funded. The company has also filed for orphan drug designation for NV-387 for the treatment of measles, Mpox, and smallpox, aiming for quicker regulatory approvals and market access due to the benefits associated with orphan drug status. Diwan highlighted the continued spread of Mpox in Africa and rising measles cases in the U.S. as a rationale for these development pathways.
2026-02-21 03:19:25
NanoViricides CEO Dr. Anil Diwan provided an update on the broad-spectrum antiviral candidate NV-387, detailing its progress in Mpox clinical development and filings for orphan drug designation. The company has completed the clinical trial application for a Phase 2 study of NV-387 for Mpox in the Democratic Republic of Congo, which is fully funded. Additionally, NanoViricides has filed orphan drug designation applications for NV-387 for the treatment of measles, Mpox, and smallpox, aiming for quicker regulatory pathways and significant benefits.
2026-02-20 19:50:11
NanoViricides CEO Dr. Anil Diwan provided an update on the company's broad-spectrum antiviral candidate, NV-387, highlighting its progress in Mpox clinical development and the filing of orphan drug designation applications for multiple indications. The company has completed the clinical trial application for a fully funded Phase 2 study of NV-387 for Mpox in the Democratic Republic of Congo and has filed for orphan drug designations for measles, Mpox, and smallpox in the US to potentially accelerate regulatory approvals and benefit from incentives.
2026-02-19 16:53:14
NanoViricides is progressing towards initiating a fully funded Phase II clinical trial for its antiviral candidate, NV-387, to treat MPox in the Democratic Republic of Congo (DRC). The company has addressed most regulatory requirements and secured funding for the trial. Additionally, NanoViricides has applied for Orphan Drug Designation for NV-387 with the U.S. FDA, which could provide significant incentives.
2026-02-19 16:53:14
NanoViricides is progressing its broad-spectrum antiviral NV-387 towards a Phase II clinical trial for Monkeypox (MPox) in the Democratic Republic of Congo, having received regulatory approval and nearing site readiness. Preclinical studies indicate NV-387's effectiveness against various viruses, and the company has filed for Orphan Drug Designation for Measles, MPox, and Smallpox. Financially, NanoViricides reported $5.29 million in cash and cash equivalents as of December 31, 2025, and believes current funding will cover the planned Phase II MPox trial.
2026-02-19 13:57:31
NanoViricides is progressing towards a fully funded Phase II clinical trial for its antiviral candidate, NV-387, targeting MPox in the Democratic Republic of Congo. The company has fulfilled most regulatory requirements for the trial and is also seeking Orphan Drug Designation from the FDA, which would provide significant incentives. NV-387 has shown efficacy in preclinical models and safety in Phase I human trials, positioning it as a promising treatment for MPox.
